Argenica Therapeutics Ltd (AGN) — Cash Flow-to-Debt Ratio
Argenica Therapeutics Ltd (AGN) has a Cash Flow-to-Debt Ratio of -3.14x as of December 2025, meaning its operating cash flow of AU$-5.51 Million could theoretically repay -3% of its total liabilities (AU$1.76 Million) in one year. Check AGN cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Argenica Therapeutics Ltd Cash Flow-to-Debt Ratio (2019–2024)
Historical debt coverage capacity for Argenica Therapeutics Ltd across 6 annual periods. Also explore balance sheet size of Argenica Therapeutics Ltd for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Argenica Therapeutics Ltd (2019–2024)
Year-by-year debt coverage analysis for Argenica Therapeutics Ltd. For market capitalisation and broader financial context, see AGN company net worth.
| Year | CF-to-Debt Ratio | Operating CF (AUD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.50x | AU$-5.70 Million | AU$3.80 Million | ▲ +28.0% |
| 2023 | -2.09x | AU$-5.06 Million | AU$2.43 Million | ▼ -18.4% |
| 2022 | -1.76x | AU$-3.30 Million | AU$1.87 Million | ▲ +61.5% |
| 2021 | -4.57x | AU$-3.36 Million | AU$735.91K | ▼ -85.8% |
| 2020 | -2.46x | AU$-1.05 Million | AU$425.72K | ▼ -1401.4% |
| 2019 | -0.16x | AU$-58.82K | AU$359.26K | — |